Investigational Drug Information for Depatuxizumab mafodotin
✉ Email this page to a colleague
What is the drug development status for Depatuxizumab mafodotin?
Depatuxizumab mafodotin is an investigational drug.
There have been 3 clinical trials for Depatuxizumab mafodotin.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 30th 2018.
The most common disease conditions in clinical trials are Glioblastoma, Glioma, and [disabled in preview]. The leading clinical trial sponsors are AbbVie, European Organisation for Research and Treatment of Cancer - EORTC, and [disabled in preview].
Summary for Depatuxizumab mafodotin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 373 |
| WIPO Patent Applications | 314 |
| Japanese Patent Applications | 86 |
| Clinical Trial Progress | Phase 2 (2018-07-30) |
| Vendors | 0 |
Recent Clinical Trials for Depatuxizumab mafodotin
| Title | Sponsor | Phase |
|---|---|---|
| UNITE Study: Understanding New Interventions With GBM ThErapy | AbbVie | Phase 3 |
| Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas | AbbVie | Phase 2 |
Clinical Trial Summary for Depatuxizumab mafodotin
Top disease conditions for Depatuxizumab mafodotin
Top clinical trial sponsors for Depatuxizumab mafodotin
US Patents for Depatuxizumab mafodotin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
